Remarkable tumor response to Iruplinalkib in a 14-year-old girl with ALK-positive advanced metastatic non–small-cell lung cancer: a case report
Targeted therapies for anaplastic lymphoma kinase (ALK) mutations in non-small cell lung cancer (NSCLC) generally extend survival and alleviate symptoms. However, significant tumor reduction or complete remission remains rare. We report a rare case of a 14-year-old girl, whose father and grandfather...
Saved in:
Main Authors: | Jiahao Wang, Qingdi Du, Xueyan Sun, Rong Tao, Zuojuan Zhang, Wei Li, Wenjing Liu, Li Wei, Zongsheng Tian, Xueliang Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1645580/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Novel ALK gene mutation in inflammatory myofibroblastic tumor of the thyroid: a case report
by: Yang Guangxu, et al.
Published: (2025-06-01) -
CLINICAL EFFICACY OF TARGETED THERAPY TOWARDS METASTATIC LUNG CANCER CARRYING DISTINCT TYPES OF ALK REARRANGEMENTS
by: N. V. Mitiushkina, et al.
Published: (2020-09-01) -
Successful use of enteric alectinib in a critically ill patient with metastatic ALK-adenocarcinoma: A case report
by: Maria Braganca, et al.
Published: (2025-12-01) -
Structural Analysis of the AlkB Family in Poultry
by: Yuling Niu, et al.
Published: (2025-07-01) -
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
by: Naoko Imanishi, et al.
Published: (2018-03-01)